期刊
TRANSCRIPTION-AUSTIN
卷 10, 期 2, 页码 118-136出版社
TAYLOR & FRANCIS INC
DOI: 10.1080/21541264.2018.1539615
关键词
CDK; transcription; RNA polymerase II; CTD; elongation
资金
- NIH/NIGMS [R01GM120109]
- NSF [MCB1817582]
- NIH/NCI [R01CA117907]
The fact that many cancer types display transcriptional addiction driven by dysregulation of oncogenic enhancers and transcription factors has led to increased interest in a group of protein kinases, known as transcriptional cyclin dependent kinases (tCDKs), as potential therapeutic targets. Despite early reservations about targeting a process that is essential to healthy cell types, there is now evidence that targeting tCDKs could provide enough therapeutic window to be effective in the clinic. Here, we discuss recent developments in this field, with an emphasis on highly-selective inhibitors and the challenges to be addressed before these inhibitors could be used for therapeutic purposes.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据